Bayer unveils drug for CKD associated with diabetes under brand name Kerendia
The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end stage renal disease or kidney failure.
Advertisement
New Delhi: Drugmaker Bayer on Thursday said it has introduced a medication for the treatment of chronic kidney disease associated with diabetes under the brand name Kerendia.
The drug is a non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease associated with type 2 diabetes.
The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end stage renal disease or kidney failure. Despite therapy, these patients often progress to kidney failure.
"Finerenone (Kerendia) therefore offers a new treatment approach for these vulnerable patients to slow down the progression of chronic kidney disease and reduce the risk of kidney failure," Bayer Zydus Pharma Managing Director Manoj Saxena said in a statement.
Diabetes is the leading cause of chronic kidney disease and end-stage kidney disease in India. Around seventy-four million people suffer from diabetes in the country and this figure is likely to increase to ninety-three million by 2030. The number of people with diabetes in India is the second highest in the world, after China.
Medical Dialogues team had earlier announced that Bayer had received marketing authorization from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for finerenone under the brand name Kerendia.
Read also: Bayer Gets Nod For Kerendia To Treat Type 2 Diabetes, CKD In Japan
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.